Market Access

“We’re going to tariff our pharmaceuticals, and once we do that, they are going to come rushing back into our country," President Donald J. Trump said during a Tuesday night dinner in Washington.

The high-stakes nature of cancer care, coupled with rapid scientific advancements and increasing payer and regulatory pressures, demands a specialized approach beyond traditional market access strategies.

A look at the current landscape and how young companies can set the stage for product launch.

HEOR scientists in the pharma industry must balance methodologic rigor with commercial expectations and timelines.

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

Biopharmas and global agencies are now prioritizing initiatives and innovations to drive speed across product development with an emphasis on getting new treatments in the hands of doctors and patients.

Demonstrating clinical benefit is the ultimate gateway to smoother patient access.

As part of the Inflation Reduction Act, price negotiations with manufacturers will begin this year, with reduced prices expected to take effect in 2027.

The biosimilars market in the US is on the rise, but barriers to greater adoption remain.

With the Inflation Reduction Act now in flux, how will the government and industry respond?

The importance of expanding your pharma sales forecasting horizon beyond the US. Learn how to effectively navigate country-specific regulatory red flags.

Identifying the inflators and deflators, and the role all stakeholders play.

Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.

In today’s pharmaceutical market access landscape, payers are not the sole decision-makers in utilization management development.

The Big Pharma commercialization playbook doesn’t work for emerging life sciences companies bootstrapping their way up. Exploring three strategies that could be the ingredients of a winning formula for startups.

A value deficit and potential consumer value proposition.

A new study found that among 2,200 patients with irritable bowel diseases, 63% encountered financial barriers that led to missed doses of medication.

Webinar Date/Time: Thu, Oct 17, 2024 11:00 AM EDT

The diversification of site-of-care delivery models is accelerating rapidly, creating new go-to-market implications for drug manufacturers—but also new opportunities to drive more fundamental innovation in engagement and access strategies.

As new litigation looms in the debate over use of copay accumulator programs, a look at potential next moves for payers—and steps drug manufacturers should take to ward off cost-driven non-adherence.

The industry holds the key to true change to the drug access landscape.

A recent study by Morningstar predicts that 16 new weight-loss drugs could be on the market by 2029.

The new vials of Zepbound are available through a new self-pay pharmacy channel, priced over 50% lower than other incretin medications for obesity.

Pharm Exec’s latest sampling of notable biopharma brand approvals and launches all have unique stories to tell—from the winding journeys to innovative “firsts” to new momentum for milestones to come.

Key approval signals progress in addressing immune-mediated inflammatory diseases.

New cardiovascular indication builds on treatment’s fast-growing legacy.

Launch campaign ramped up for disease-modifying drug that targets rare and fatal form of hypertension.

How drugmakers can reap value from using generative AI in their market-entry strategies and decision-making, including mitigating launch challenges and enhancing the customer conversation.

The importance of pre-approval information exchange (PIE) with payers and other strategic considerations to help navigate today’s market access challenges and regulatory requirements in bringing promising cell and gene therapies to the market.

One, tackle by price; the other, tackle with data.